BioMedha is a UK-based pre-clinical contract research organisation, providing bioscience expertise to the global drug discovery industry. Our team of industry-experienced In vitro biology-focused scientists undertake key elements of the early-stage drug discovery process, helping you to accelerate your drug discovery.
We are Human Tissue Act (HTA) authorised establishment with on-site blood donor panel supporting drug discovery biology projects in immunology, oncology, immuno-oncology, and inflammation therapeutic areas.
We bring extensive drug discovery biology expertise in:
- Hypothesis testing, target validation, assay development, screening from hit to lead and through to candidate selection, and Mechanism of action studies
- Whole blood assays and immune cell assays
- Flow cytometry expertise
- Cytokine assays and Luminex multiplexing
- Cell imaging
- Expression studies (protein, mRNA, secretion, surface expression)
- Functional assays (cytokines, bioassays, receptor, and signaling pathways)
- Target knockdown and over-expression studies
- GPCR assay development and screening
- Biochemical assays and Protein-protein interactions
- Discovery toxicology studies
Our goal is to simplify early-stage drug discovery by supporting our clients’ In vitro biology projects. Using our robust platforms which can be tailored to meet your specific needs, our experienced team of bioscientists provide the support needed to advance and accelerate your drug discovery.
